Clinical trial
2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic…
NCT00483067 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00483067 |
|---|---|
| Title | 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES) |
| Official title | Phase II Study: 2-Chlorodeoxyadenosine (2-CdA) and Cytarabine (Ara-C) in Idiopathic Hypereosinophilic Syndrome (HES) |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | 2-CdA, Ara-C, G-CSF (Granulocyte colony-stimulating factor) |
| Enrollment | 13 |
| Start date | Mar 1, 1998 |
| Primary completion | Mar 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Jun 6, 2007 |
| Last update posted | Aug 2, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: